Stock market today:S&P 500 climbs as Trump U.S.-China, regional banks worries cool
TURKU, FINLAND - Faron Pharmaceuticals Ltd (AIM:FARN, First North: FARON), a company specializing in novel immunotherapies, disclosed that founders Markku Jalkanen, a director, and his spouse Sirpa Jalkanen have donated a significant number of shares to a Finnish medical research foundation. On June 3, 2025, the couple gave 500,000 ordinary shares to the "Sirpa ja Markku Jalkasen Säätiö sr," aiming to support high-quality medical research in Finland.
Markku Jalkanen contributed 400,000 shares, while Sirpa Jalkanen donated 100,000 shares. With this donation, the foundation now holds approximately 0.45 percent of the total voting rights in Faron Pharmaceuticals. The foundation operates independently from its benefactors.
In a related transaction on the same day, the Jalkanens also sold a combined total of 300,000 ordinary shares of the company, with Markku Jalkanen selling 200,000 shares and Sirpa Jalkanen selling 100,000 shares. After these transactions, Markku Jalkanen’s interest in the company stands at 1,625,266 ordinary shares (1.45% of voting rights), and Sirpa Jalkanen’s at 988,168 shares (0.88% of voting rights). Collectively, the couple now holds approximately 2.33 percent of the voting rights in Faron Pharmaceuticals.
The announcement follows the company’s guidelines for transparency in dealings by directors and persons closely associated with them. The move by the Jalkanens reflects their ongoing support for medical research beyond their corporate roles, while also adjusting their personal stakes in the company.
This information is based on a press release statement from Faron Pharmaceuticals Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.